Accelerating GPRC5D Therapy: Proteins, mAbs and CAR-T
GPRC5D plays a pivotal role in cancer and immunology research, garnering significant industry attention. At DIMA Biotechnology, we provide essential tools for exploring this promising target. Our offerings include functional active proteins and specialized antibodies, with a particular focus on GPRC5D CAR-T molecules, which have progressed from leads to Investigator-Initiated Trial (IIT) clinical trial stages in collaboration with our partners. Preliminary data from ongoing clinical trials showcase remarkable clinical efficacy, particularly in treating RRMM patients. Our proprietary technology platforms streamline drug discovery processes, offering comprehensive support to expedite therapeutic research and development.
GPRC5D Background
In recent developments, LaNova’s LM-305, an ADC targeting GPRC5D, secured an exclusive global license with AstraZeneca, resulting in an immediate payment of $55 million and the potential for milestone payments totaling $545 million. Concurrently, OriCell Therapeutics introduced OriCAR-017, marking China’s first CAR-T cell therapy designed to target GPRC5D. Additionally, Janssen’s talquetamab, a GPRC5D/CD3 bispecific antibody, displayed promising results in treating RRMM patients, with an anticipated U.S. launch as early as 2024. These advancements underscore the dynamic landscape of GPRC5D-targeted drugs and their potential to revolutionize the pharmaceutical industry.
GPRC5D Products
Can’t find the right product? Please fill up the following form and let us know your special needs. We will get back to you shortly with our solutions.
We have various technologies for antibody-based drug development. Here is a summary of our platforms:
1. DiMProTM membrane protein platform: Use mammalian cells to express and purify membrane proteins. We have over 1000 on-shelf functional proteins, out of which, 50+ are active full-length multi-pass membrane proteins. For multi-pass transmembrane proteins, such as GPCRs and ion channels, we have five different solutions, i.e., Membrane Nanoparticle (MNP), Virus-Like Particle (VLP), Exosome (EXO), Detergent and Nanodisc.
2. DimAb® single B-cell antibody discovery platform: Our DimAb® B cell library can help customers easily obtain over 10,000 positive hits in as short as a month’s time.
3. DiLibraryTM mammalian display antibody engineering platform: A proprietary platform works great for antibody humanization, affinity maturation and other engineering applications. The developability of Ab molecules engineered from this system is much better than Abs from phage or yeast display platforms.